A general synthetic strategy featuring a diastereoselective intramolecular Pauson–Khand reaction (IPKR) and some tactical synthetic manoeuvres to access ten iridoids in a stereocontrolled manner is delineated.
Experimental 13C kinetic isotope effects (KIEs)
and
density functional theory (DFT) calculations are used to evaluate
the mechanism and origin of enantioselectivity in the formal C(sp2)–H alkylative desymmetrization of cyclopentene-1,3-diones
using nitroalkanes as the alkylating agent. An unusual combination
of an inverse (∼0.980) and a normal (∼1.033) KIE is
observed on the bond-forming carbon atoms of the cyclopentene-1,3-dione
and nitroalkane, respectively. These data provide strong support for
a mechanism involving reversible carbon–carbon bond formation
followed by rate- and enantioselectivity-determining nitro group elimination.
The theoretical free-energy profile and the predicted KIEs indicate
that this elimination event occurs via an E1cB pathway. The origin
of remote stereocontrol is evaluated by distortion–interaction
and SAPT0 analyses of the E1cB transition states leading to both enantiomers.
Ladderane phospholipids, with their unusual ladder-like arrangement of concatenated cyclobutane rings, represent an architecturally unique class of natural products. However, despite their fascinating structure and other necessary impetus, only a few synthetic studies of these molecules have been reported so far. We have now devised a concise total synthesis of [3]-ladderanol, a component of natural ladderane phospholipids, using an organocatalytic enantioselective desymmetrizing formal C(sp 2 )À H alkylation. Our synthetic strategy rests on the late-stage introduction of chirality, thus allowing facile access to both enantiomers of [3]-ladderanol as well as an analogue. This is the first time a desymmetrization strategy is applied to the synthesis of [3]-ladderanol. The scope of this desymmetrizing C(sp 2 )À H alkylation of meso-cyclobutane-fused cyclohexenediones is also presented.
Ladderane phospholipids, with their unusual ladder‐like arrangement of concatenated cyclobutane rings, represent an architecturally unique class of natural products. However, despite their fascinating structure and other necessary impetus, only a few synthetic studies of these molecules have been reported so far. We have now devised a concise total synthesis of [3]‐ladderanol, a component of natural ladderane phospholipids, using an organocatalytic enantioselective desymmetrizing formal C(sp2)−H alkylation. Our synthetic strategy rests on the late‐stage introduction of chirality, thus allowing facile access to both enantiomers of [3]‐ladderanol as well as an analogue. This is the first time a desymmetrization strategy is applied to the synthesis of [3]‐ladderanol. The scope of this desymmetrizing C(sp2)−H alkylation of meso‐cyclobutane‐fused cyclohexenediones is also presented.
Ladderane phospholipids, with their unusual ladder-like arrangement of fused cyclobutane rings, represent an architecturally unique class of natural products. However, despite their fascinating structure and other necessary impetus, only a few synthetic studies of these molecules have been reported so far. We have now devised a concise synthesis of [3]-ladderanol, a component of ladderane phospholipids, using an organocatalytic enantioselective desymmetrizing formal C(sp2)‒H alkylation. Our synthetic strategy rests on a late-stage introduction of chirality, thus allowing facile access to both the enantiomers of [3] ladderanol as well as its analog. This is the first time a desymmetrization strategy is applied to the synthesis of [3]-ladderanol. The scope of this desymmetrizing C(sp2)‒H alkylation of meso cyclobutane fused cyclohexenediones is also presented.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.